RE: GREAT TIME TO BUY AVCT8 Jun 2020 04:02
Today’s Times
Astrazeneca has abandoned a tentative interest in combining with an American rival behind remdesivir, the coronavirus treatment.
The London-listed, Cambridge-based pharmaceuticals company made a preliminary approach to Gilead Sciences last month, according to Bloomberg.
However, sources talked down the prospect of any Astrazeneca interest yesterday.
IN YOUR INBOX
Your daily Business Briefing
Keep up to date by getting our Times Business Briefing newsletter straight to your inbox at 8am and lunchtime
Sign up now
The Anglo-Swedish company is thought to have ruled out any deal because it would have distracted it from developing its own drugs pipeline, especially promising oncology drugs, and from attempts to produce a successful coronavirus vaccine.
There was scepticism, too, that such a huge deal could be put together because of logistical problems posed by lockdowns. Astrazeneca is valued at £111 billion on the FTSE 100, making it one of Britain’s most valuable publicly quoted companies, and the New York-listed Gilead has a market capitalisation of $96 billion.